Viridian Therapeutics, Inc.\DE (VRDN) Cash from Discontinued Operations (2013)

Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Cash from Discontinued Operations of 50125.0 for Q4 2013, little changed quarter-over-quarter from 50000.0 in Q3 2013.

Viridian Therapeutics, Inc.\DE (VRDN) Cash from Discontinued Operations (2013) Analysis & Trends

Viridian Therapeutics, Inc.\DE's Cash from Discontinued Operations history runs 1 years deep, the most recent figure standing at 50125.0 for Q4 2013.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 7.90 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Viridian Therapeutics, Inc.\DE 2.50 Bn 2.50 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2013 -50,125.00
Dec 31, 2013 -50,125.00
Sep 30, 2013 -50,000.00
Sep 30, 2013 -50,000.00